MAX: A Potential Drug Target and Biomarker for Helix-Loop-Helix Proteins

Target Name: MAX

NCBI ID: G4149

Content of Review Report on MAX Target / Biomarker

MAX

MAX: A Potential Drug Target and Biomarker for Helix-Loop-Helix Proteins

Introduction

Helix-loop-helix (HLH) proteins are a family of non-coding RNAs that play a crucial role in various cellular processes, including DNA replication, gene regulation, and cell signaling. MAX, a representative member of this family, has been identified as a potential drug target and biomarker. This article will provide an overview of MAX, its functions, and potential as a drug target and biomarker.

FUNCTIONAL DEFINITION OF MAX

MAX is a 21-kDa protein that belongs to the MAX family of HLH proteins. This family also includes the homeodetic transcription factor MAX (EMX), and the heat shock protein HSP70. MAX is expressed in various tissues and cells, including muscle, liver , and brain. It plays a critical role in cell signaling, DNA replication, and gene regulation.

MAX regulates DNA replication by interacting with the enzyme DNA polymerase II (DPI). This interaction allows MAX to regulate the rate of DNA synthesis and maintain accurate genomic copies. In addition, MAX has been shown to play a role in cell signaling by regulating the expression of various genes.

MAX has also been shown to play a key role in the regulation of cell apoptosis. When MAX is activated, it can induce cell apoptosis, which is a natural response to harmful cellular stimuli, such as UV radiation, chemotherapy, or infection. This finding makes MAX an attractive drug target for diseases that are characterized by apoptosis, such as cancer, neurodegenerative diseases, and FSCN3-mediated diseases.

MAX AS A POTENTIAL DRUG TARGET

MAX has been identified as a potential drug target due to its various functions, including its role in cell signaling, DNA replication, and cell apoptosis.MAX has been shown to interact with various drug targets, including SMAD, NF-kappa-B, and TGF- 尾. These interactions make MAX potential targets for small molecules, antibodies, and other therapeutic agents.

One of the main advantages of MAX as a drug target is its therapeutic potential in diseases characterized by apoptosis. MAX has been shown to play a key role in the regulation of cell apoptosis, which can be exploited to develop new treatments for diseases that are characterized by apoptosis, such as cancer, neurodegenerative diseases, and FSCN3-mediated diseases.

MAX may also serve as a biomarker for various diseases. Its role in cell signaling and DNA replication makes it an attractive target for biomarkers that can be used to diagnose and monitor disease progress. For example, MAX has been shown to be downregulated in various diseases, including cancer, and its levels have been used as a biomarker to predict disease outcomes.

MAX ASSOCIATED WITH DISEASES

MAX has been associated with several diseases, including cancer, neurodegenerative diseases, and FSCN3-mediated diseases.

In cancer, MAX has been shown to play a role in the regulation of DNA replication, gene expression, and cell apoptosis. MAX has also been shown to interact with various cancer-related genes, including TP53, PIK3CA, and NF-kappa-B. These interactions make MAX potential targets for cancer therapies that target these genes.

In neurodegenerative diseases, MAX has been shown to play a role in the regulation of protein synthesis, including the synthesis of neurotransmitter receptors, such as dopamine and serotonin.MAX has also been shown to interact with various neurodegenerative disease-related genes, including SNAP25, TrkA, and Calbindin. These interactions make MAX potential targets for neurodegenerative disease therapies that target these genes.

In addition, MAX has

Protein Name: MYC Associated Factor X

Functions: Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MYC or MAD which recognizes the core sequence 5'-CAC[GA]TG-3'. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor. May repress transcription via the recruitment of a chromatin remodeling complex containing H3 'Lys-9' histone methyltransferase activity. Represses MYC transcriptional activity from E-box elements

The "MAX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets